0001564590-21-043081 | 10-Q | XBRL Viewer

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2021	Aug. 06, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001439725
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-39659
Entity Registrant Name	BIODESIX, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-3986492
Entity Address, Address Line One	2970 Wilderness Place,
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Boulder
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80301
City Area Code	303
Local Phone Number	417-0500
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	BDSX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		26,970,640

Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 56,349	$ 62,126
Accounts receivable, net of allowance for doubtful accounts of $168 and $180	5,281	15,304
Other current assets	6,820	8,710
Total current assets	68,450	86,140
Non‑current assets
Property and equipment, net	3,378	3,178
Intangible assets, net	12,400	13,260
Other long-term assets	2,545	3,461
Goodwill	15,031	15,031
Total non‑current assets	33,354	34,930
Total assets	101,804	121,070
Current liabilities
Accounts payable	1,160	8,964
Accrued liabilities	6,198	7,789
Deferred revenue	2,182	3,532
Current portion of contingent consideration	8,626
Current portion of notes payable	3,106	11,840
Total current liabilities	21,272	32,125
Non‑current liabilities
Long‑term notes payable, net of current portion	29,955	15,926
Contingent consideration	23,217	29,932
Other long-term liabilities	1,587	1,921
Total non‑current liabilities	54,759	47,779
Total liabilities	76,031	79,904
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.001 par value, 5,000,000 shares authorized; 0 (2021 and 2020) shares issued and outstanding
Common stock, $0.001 par value, 200,000,000 shares authorized; 26,948,879 (2021) and 26,561,504 (2020) shares issued and outstanding	27	27
Additional paid‑in capital	302,923	299,953
Accumulated deficit	(277,177)	(258,814)
Total stockholders' equity	25,773	41,166
Total liabilities and stockholders' equity	$ 101,804	$ 121,070

Condensed Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts receivable	$ 168	$ 180
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	200,000,000	200,000,000
Common stock, issued	26,948,879	26,561,504
Common stock, outstanding	26,948,879	26,561,504

Condensed Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenues	$ 11,885	$ 4,239	$ 40,751	$ 9,335
Operating expenses:
Direct costs and expenses	7,085	1,874	25,303	3,455
Research and development	3,323	2,107	6,644	5,007
Sales, marketing, general and administrative	11,425	6,834	23,352	14,914
Change in fair value of contingent consideration	639	(957)	1,622
Total operating expenses	22,472	9,858	56,921	23,376
Loss from operations	(10,587)	(5,619)	(16,170)	(14,041)
Other income (expense):
Interest expense	(815)	(2,784)	(1,466)	(4,241)
Change in fair value of warrant liability		4		55
Loss on debt extinguishment			(728)
Other income, net		133	1	256
Total other expense	(815)	(2,647)	(2,193)	(3,930)
Net loss	$ (11,402)	$ (8,266)	$ (18,363)	$ (17,971)
Net loss per share, basic and diluted	$ (0.41)	$ (30.06)	$ (0.68)	$ (68.85)
Weighted-average shares outstanding, basic and diluted	27,730	275	27,020	261

Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Convertible Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balances at Dec. 31, 2019	$ (225,139)		$ 1	$ 2,324	$ (227,464)
Temporary Equity Balance, Shares at Dec. 31, 2019		118,766
Temporary Equity Balance at Dec. 31, 2019		$ 193,959
Common Stock Balance, Shares at Dec. 31, 2019			255
Exercise of stock options	11			11
Exercise of stock options, shares			20
Net loss	(9,705)				(9,705)
Balances at Mar. 31, 2020	(234,833)		$ 1	2,335	(237,169)
Temporary Equity Balance, Shares at Mar. 31, 2020		118,766
Temporary Equity Balance at Mar. 31, 2020		$ 193,959
Common Stock Balance, Shares at Mar. 31, 2020			275
Balances at Dec. 31, 2019	(225,139)		$ 1	2,324	(227,464)
Temporary Equity Balance, Shares at Dec. 31, 2019		118,766
Temporary Equity Balance at Dec. 31, 2019		$ 193,959
Common Stock Balance, Shares at Dec. 31, 2019			255
Net loss	(17,971)
Balances at Jun. 30, 2020	(243,044)		$ 1	2,390	(245,435)
Temporary Equity Balance, Shares at Jun. 30, 2020		118,766
Temporary Equity Balance at Jun. 30, 2020		$ 193,959
Common Stock Balance, Shares at Jun. 30, 2020			275
Balances at Mar. 31, 2020	(234,833)		$ 1	2,335	(237,169)
Temporary Equity Balance, Shares at Mar. 31, 2020		118,766
Temporary Equity Balance at Mar. 31, 2020		$ 193,959
Common Stock Balance, Shares at Mar. 31, 2020			275
Stock‑based compensation	55			55
Net loss	(8,266)				(8,266)
Balances at Jun. 30, 2020	(243,044)		$ 1	2,390	(245,435)
Temporary Equity Balance, Shares at Jun. 30, 2020		118,766
Temporary Equity Balance at Jun. 30, 2020		$ 193,959
Common Stock Balance, Shares at Jun. 30, 2020			275
Balances at Dec. 31, 2020	41,166		$ 27	299,953	(258,814)
Common Stock Balance, Shares at Dec. 31, 2020			26,562
Exercise of stock options	475			475
Exercise of stock options, shares			223
Stock‑based compensation	1,752			1,752
Net loss	(6,961)				(6,961)
Balances at Mar. 31, 2021	36,432		$ 27	302,180	(265,775)
Common Stock Balance, Shares at Mar. 31, 2021			26,785
Balances at Dec. 31, 2020	$ 41,166		$ 27	299,953	(258,814)
Common Stock Balance, Shares at Dec. 31, 2020			26,562
Exercise of stock options, shares	366,000
Net loss	$ (18,363)
Balances at Jun. 30, 2021	25,773		$ 27	302,923	(277,177)
Common Stock Balance, Shares at Jun. 30, 2021			26,949
Balances at Mar. 31, 2021	36,432		$ 27	302,180	(265,775)
Common Stock Balance, Shares at Mar. 31, 2021			26,785
Exercise of stock options	204			204
Exercise of stock options, shares			164
Stock‑based compensation	539			539
Net loss	(11,402)				(11,402)
Balances at Jun. 30, 2021	$ 25,773		$ 27	$ 302,923	$ (277,177)
Common Stock Balance, Shares at Jun. 30, 2021			26,949

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

Condensed Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
Condensed Statements of Cash Flows - USD ($) $ in Thousands	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities
Net loss	$ (18,363)	$ (17,971)
Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities
Depreciation and amortization	1,523	1,391
Amortization of convertible notes debt discount		2,611
Loss on extinguishment of term loan	728
Stock‑based compensation expense	2,291	55
Change in contingent consideration	1,622
Provision for doubtful accounts	193	113
Accrued interest, amortization of debt issuance costs and other	502	662
Changes in operating assets and liabilities:
Accounts receivable	9,830	2,233
Other current assets	1,794	(876)
Other long-term assets and liabilities	447
Accounts payable and other accrued liabilities	(9,453)	(210)
Deferred revenue	(1,350)	3,152
Net cash and cash equivalents and restricted cash used in operating activities	(10,236)	(8,840)
Cash flows from investing activities
Purchases of property and equipment	(747)	(232)
Patent costs and intangible asset acquisition, net	(117)	(86)
Payment to acquire Oncimmune assets		(500)
Net cash and cash equivalents and restricted cash used in investing activities	(864)	(818)
Cash flows from financing activities
Proceeds from issuance of convertible debt payable		12,955
Proceeds from exercise of stock options	679	11
Proceeds from term loan and notes payable	30,078	3,085
Repayment of term loan and notes payable	(25,419)
Payment of debt issuance costs	(109)
Other		(5)
Net cash and cash equivalents and restricted cash provided by financing activities	5,229	16,046
Net (decrease) increase in cash and cash equivalents and restricted cash	(5,871)	6,388
Cash, cash equivalents, and restricted cash ‑ beginning of period	62,306	5,468
Cash, cash equivalents, and restricted cash ‑ end of period	$ 56,435	$ 11,856

Organization and Description of Business

6 Months Ended

Jun. 30, 2021

Organization And Description Of Business [Abstract]

Organization and Description of Business

Note 1 – Organization and Description of Business

Biodesix, Inc. (the “Company”, “Biodesix”, “we” “us” and “our”), formerly Elston Technologies, Inc., was incorporated in Delaware in 2005. The Company’s headquarters are in Colorado, with laboratories in Colorado and Kansas. The Company conducts all of its operations within a single legal entity. Biodesix is a data-driven diagnostic solutions company leveraging state of the art technologies with its proprietary artificial intelligence platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. In addition to diagnostic tests, the Company provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics.

The Company performs its blood-based diagnostic tests in its laboratory facilities, which are located in Boulder, Colorado and De Soto, Kansas. In May 2020, the Federal Drug Administration (FDA) authorized performance of the Bio-Rad SARS-CoV-2 Droplet Digital™ polymerase chain reaction (ddPCR) test to detect Coronavirus Disease 2019 (COVID-19) infection. In April 2020, the FDA authorized the Platelia SARS-CoV-2 Total Ab test to detect COVID-19 antibodies. Medical products that are granted an Emergency Use Authorization (EUA) are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety.

Blood-Based Lung Tests

The Company offers four blood-based lung cancer tests across the lung cancer continuum of care:

•

Nodify XL2® and Nodify CDT™ tests, marketed as part of our Nodify Lung® Nodule Risk Assessment testing strategy, assess the risk of lung cancer to help identify the most appropriate treatment pathway. We believe we are the only company to offer two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules.

•

GeneStrat® and VeriStrat® tests, marketed as part of our Biodesix Lung Reflex® testing strategy, are used following diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient’s immune system to establish the patient’s prognosis and help guide treatment decisions. The GeneStrat tumor profiling test and the VeriStrat immune profiling test have a 36-hour average turnaround time, providing physicians with timely results to facilitate treatment decisions.

COVID-19 Tests

Using the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab tests, we operate and have commercialized the Biodesix WorkSafe™ testing program. The Company offers three SARS-CoV-2 tests under the Biodesix WorkSafe™ testing program:

•

Bio-Rad SARS-CoV-2 ddPCR test, which is authorized by the FDA to be performed by Clinical Laboratory Institute Amendments (CLIA) authorized laboratories that perform high complexity tests. The ddPCR test is designed to detect the presence of infection by the SARS-CoV-2 virus.

•

Platelia SARS-CoV-2 Total Ab test, which is an antibody test, authorized by the FDA, intended for detecting a B-cell immune response to SARS-CoV-2, indicating recent or prior infection.

•

cPass™ SARS-CoV-2 Neutralization Antibody Test, which is the first and only blood-based surrogate neutralizing antibody test with FDA EUA and uses ELISA technology to qualitatively detect circulating neutralizing antibodies to the receptor binding domain (RBD) in the spike protein of SARS-CoV-2 that are produced in response to vaccination or a previous SARS-CoV-2 infection. This test was commercially introduced during the second quarter 2021 in partnership with GenScript Biotech Corporation.

These tests under the Biodesix WorkSafe™ testing program are utilized by healthcare providers, including hospitals and nursing homes, and are also offered to businesses and educational systems to assist in their back-to-work or back-to-school strategies, a crucial element of restarting economic activity.

In developing the Company's products, the Company has built or gained access to unique biorepositories, proprietary technology, and bioinformatics methods that it believes are important to the development of new targeted therapies, determining clinical trial eligibility and guiding treatment selection.

All of the Company’s testing services are made available through its clinical laboratories.

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X for interim financial information and reflect all adjustments necessary to state fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. All such adjustments are of a normal recurring nature. Results for interim periods are not indicative of the results for the entire fiscal year. The accompanying Condensed Financial Statements should be read in conjunction with the audited Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. Certain information and footnote disclosures, including significant accounting policies, normally included in fiscal year financial statements prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”) have been condensed or omitted. The Condensed Balance Sheet as of December 31, 2020 was derived from the audited financial statements.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the balance sheet date and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.

Concentration of Credit Risk and Other Uncertainties

Substantially all of the Company’s cash and cash equivalents are deposited with two major financial institutions in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents. Restricted cash consists of deposits related to the Company’s corporate credit cards and prior to March 31, 2021, also included a letter of credit related to an operating lease agreement. As of June 30, 2021 and December 31, 2020, the Company had $0.1 million and $0.2 million in restricted cash, respectively, which was included in ‘Other current assets’ in the accompanying balance sheets.

Several of the components for certain of the Company's sample collection kits, test reagents, and test systems are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.

For a discussion of credit risk concentration of accounts receivable as of June 30, 2021 and 2020, see Note 9 – Revenue & Accounts Receivable Credit Concentration.

Inventory

Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to ‘Direct costs and expenses’. Inventory is stated at cost and reported within ‘Other current assets’ in the balance sheet and was $3.1 million and $3.2 million as of June 30, 2021 and December 31, 2020, respectively.

Fair Value of Financial Instruments

U.S. GAAP for fair value establishes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach, and cost approach). We utilize a combination of market and income approaches to value our financial instruments. Our financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. Fair value measurements are categorized within the fair value hierarchy based upon the lowest level of the most significant inputs used to determine fair value. The three levels of the hierarchy and the related inputs are as follows:

Level		Inputs
1		Unadjusted quoted prices in active markets for identical assets and liabilities.
2		Unadjusted quoted prices in active markets for similar assets and liabilities;
		Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or
		Inputs other than quoted prices that are observable for the asset or liability.
3		Unobservable inputs for the asset or liability.

The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.

See Note 4 — Fair Value for further discussion related to estimated fair value measurements.

Recently Issued Accounting Standards

6 Months Ended

Jun. 30, 2021

New Accounting Pronouncements And Changes In Accounting Principles [Abstract]

Recently Issued Accounting Standards

Note 3 - Recently Issued Accounting Standards

Standards Being Evaluated

In February 2016, the FASB issued ASU No. 2016-02, Leases (ASC Topic 842). The new guidance maintains two classifications of leases: finance leases, which replace capital leases, and operating leases. Lessees will need to recognize a right-of-use asset and a lease liability on the balance sheet for those leases previously classified as operating leases under the old guidance. The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for direct costs. The accounting standard will be effective for the Company beginning January 1, 2022. The Company is currently evaluating this guidance and assessing the overall impact on its financial statements.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (ASC Topic 326). This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2023 with early adoption permitted. The Company is currently evaluating this guidance and assessing the overall impact on its financial statements.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI http://asc.fasb.org/topic&trid=2122394

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)(2)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-URI http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(1)

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(2)

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)

+ Details

Fair Value

6 Months Ended

Jun. 30, 2021

Fair Value Disclosures [Abstract]

Fair Value

Note 4 - Fair Value

Recurring Fair Value Measurements

Our borrowing instruments are recorded at their carrying values in the balance sheets, which may differ from their respective fair values. The fair values of outstanding borrowings, which are classified as Level 2, approximate their carrying values as of June 30, 2021 and December 31, 2020, based on interest rates currently available for similar borrowings and were (in thousands):

	As of
	June 30, 2021				December 31, 2020
	Carrying Value		Fair Value		Carrying Value		Fair Value
Borrowings	$	33,061	$	33,061	$	27,766	$	27,766

The financial liabilities that are measured and recorded at estimated fair value on a recurring basis consist of our contingent consideration associated with our acquisition of Integrated Diagnostics, Inc. (Indi), and prior to the completion of our initial public offering in October 2020, the warrant liability, put option liability and contingent value rights granted to certain holders of our convertible preferred stock and debt instruments, which were accounted for as liabilities and remeasured through our statements of operations. The table below presents the reported fair values of contingent consideration, which is classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands):

Description	June 30, 2021		December 31, 2020
Current portion of contingent consideration	$	8,626	$	—
Contingent consideration		23,217		29,932
Total contingent consideration	$	31,843	$	29,932

The following table presents the changes in contingent consideration for the six months ended June 30, 2021 (in thousands):

Level 3 Rollforward	For the Six Months Ended June 30, 2021
Beginning balances - January 1, 2021	$	29,932
Changes in fair value		1,622
Interest expense		289
Ending balances - June 30, 2021	$	31,843

The following table presents the changes in these financial liabilities for the six months ended June 30, 2020 (in thousands):

	For the Six Months Ended June 30, 2020
Level 3 Rollforward	Contingent Consideration		Put Option Liability		Warrant Liability			Contingent Value Rights
Beginning balances - January 1, 2020	$	29,114	$	3,261	$	372		$	60
Additions		—		3,340		—			—
Changes in fair value		—		—		(55	)		—
Ending balances - June 30, 2020	$	29,114	$	6,601	$	317		$	60

Contingent Consideration

In connection with the acquisition of Indi in 2018, the Company recorded contingent consideration for amounts contingently payable to Indi's selling shareholders pursuant to the terms of the asset purchase agreement. The contingent consideration arrangement requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month gross margin target of $2.0 million within the seven-year period after the acquisition date. Under the terms of the agreement, when the gross margin target is met the Company is required to issue 2,520,108 shares of common stock. For the six months following the achievement of the gross margin target, Indi has the option to require the Company to redeem these common shares for $37.0 million in cash over eight equal quarterly installments. If Indi elects to not exercise its option, the Company has 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million.

The Company met the gross margin target of $2.0 million for three consecutive months during the three months ended June 30, 2021. As a result of the achievement of the gross margin target, the Company entered into an amendment to the original agreement in August 2021 in which the Company has agreed to forgo the issuance of common stock and will make six quarterly installments of approximately $4.6 million beginning in January 2022 and a final payment of approximately $9.3 million in July 2023 for a total of $37.0 million. The aggregate amount of payments owed by the Company under this amendment is the same as if Indi had exercised the put right or the Company had exercised the call right provided for in the original agreement.

The significant unobservable inputs used in the measurement of fair value include the probability of successful achievement of the specified product gross margin targets, the period in which the targets were expected to be achieved, and discount rates which ranged from 11% to 13.5%. As a result of the achievement of the gross margin target, the only significant unobservable input used in the measurement of fair value includes the discount rate since all other inputs became fixed and determinable. Significant increases or decreases in the discount rate would result in a significantly higher or lower fair value measurement.

Contingent consideration expected to be paid in the next twelve months is recorded in the balance sheets as ‘Current portion of contingent consideration’ while the remaining amount to be paid is recorded as ‘Contingent consideration’ within non-current liabilities. The net change to contingent consideration through the date the gross margin target was met is recorded as operating expenses in the statements of operations. Subsequent changes to the contingent consideration following the achievement of the gross margin target are recorded as ‘Interest expense’ in the statements of operations resulting from the passage of time and fixed payment schedule. The net change to contingent consideration recorded as operating expenses during the three and six months ended June 30, 2021 was an increase of $0.6 million and $1.6 million, respectively. The net change to contingent consideration recorded as ‘Interest expense’ during both the three and six months ended June 30, 2021 was an increase of $0.3 million. The net change to contingent consideration recorded as operating expenses during the three and six months ended June 30, 2020 was a decrease of $1.0 million and zero, respectively.

Put Option Liability

The put option liability was valued based on the calculated returns as a result of the various discounts included in the Company’s convertible notes payable and the related probability assessments of the various settlement scenarios. During the six months ended June 30, 2020, the Company recognized an addition to the put option liability of $3.3 million in connection with a favorable conversion rate granted to holders of issued convertible debt. The put option liability was settled upon the closing of the Company’s initial public offering in October 2020 and reclassified to additional paid-in capital.

Warrant Liability

In connection with entering into the 2018 Notes (see Note 6 – Debt), the Company issued to the lender a warrant to purchase 613,333 shares of Series G convertible preferred stock, at an exercise price of $0.75 per share, subject to adjustment upon specified dilutive issuances. The warrant was immediately exercisable upon issuance and expires on February 23, 2028. The estimated fair value of the warrant on the issuance date of $0.3 million was recorded as a debt discount and as a preferred stock warrant liability. Through the

effective date of the Company’s initial public offering in October 2020, the Series G warrants were remeasured to an estimate of fair value using a Black Scholes pricing model. As a result of the Company’s initial public offering, the preferred stock warrants were automatically converted to warrants to purchase 103,326 shares of common stock with a weighted average exercise price of $4.46 and were also transferred to additional paid-in capital. During the six months ended June 30, 2020, the Company recorded a decrease in the value of the warrant liability of $0.1 million.

Contingent Value Rights

In addition to the shares of Series F Preferred Stock that were issued in January 2016, investors who purchased more than their pro‑rata amount in the financing described above received a calculated number of contingent value rights (CVRs). In connection with the Series F financing, the Company issued 3,999 CVRs originally valued at $0.5 million. One CVR represents 0.00375% of the Company’s interest in the drug ficlatuzumab. The initial estimated value of the CVRs were recorded as a liability and as a reduction to the Series F proceeds. Upon receipt by the Company or a milestone, royalty, or any other type of payment from the Company’s ownership rights in the drug, the Company was required to make a cash payment to the CVR holders equal to 15% of net proceeds, as defined. In September 2020, the Company exercised its opt-out right with AVEO Oncology (AVEO) for the payment of 50% of development and regulatory costs for ficlatuzumab. As a result, the CVRs were settled effective December 2, 2020. See Note 13 – Commitments and Contingencies for a discussion of the Co-Development Agreement with AVEO.

Non-Financial Assets and Liabilities

Our non-financial assets, which primarily consist of property and equipment, goodwill, and other intangible assets, are not required to be carried at fair value on a recurring basis and are reported at carrying value. There were no changes to the valuation methods during the periods presented.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Supplementary Balance Sheet Information

6 Months Ended

Jun. 30, 2021

Balance Sheet Related Disclosures [Abstract]

Supplementary Balance Sheet Information

Note 5 – Supplementary Balance Sheet Information

Property and equipment consist of the following (in thousands):

	June 30, 2021			December 31, 2020
Lab equipment	$	6,197		$	5,730
Leasehold improvements		2,032			1,845
Computer equipment		871			871
Furniture and fixtures		424			424
Software		655			651
Vehicles		97			—
Construction in process		195			381
		10,471			9,902
Less: accumulated depreciation		(7,093	)		(6,724	)
Total property and equipment, net	$	3,378		$	3,178

Depreciation expense for the three and six months ended June 30, 2021 was $0.2 million and $0.5 million, respectively, compared to $0.2 million and $0.4 million for the three and six months ended June 30, 2020, respectively.

Intangible assets, excluding goodwill, consist of the following (in thousands):

	June 30, 2021							December 31, 2020
	Cost		Accumulated Amortization			Net Carrying Value		Cost		Accumulated Amortization			Net Carrying Value
Intangible assets subject to amortization
Patents	$	1,590	$	(533	)	$	1,057	$	1,474	$	(494	)	$	980
Purchased technology		16,900		(5,633	)		11,267		16,900		(4,694	)		12,206
Intangible assets not subject to amortization
Trademarks		76		—			76		74		—			74
Total	$	18,566	$	(6,166	)	$	12,400	$	18,448	$	(5,188	)	$	13,260

Amortization expense related to definite-lived intangible assets was $0.5 million and $1.0 million for the three and six months ended June 30, 2021 and 2020, respectively. Future estimated amortization expense of intangible assets is (in thousands):

	As of
	June 30, 2021
Remainder of 2021	$	976
2022		1,951
2023		1,947
2024		1,940
2025		1,936
2026 and thereafter		3,574
Total	$	12,324

Accrued liabilities consist of the following (in thousands):

	June 30, 2021		December 31, 2020
Compensation related accruals	$	2,117	$	3,975
Accrued clinical trial expense		842		715
Other expenses		3,239		3,099
Total accrued liabilities	$	6,198	$	7,789

Debt

6 Months Ended

Jun. 30, 2021

Debt Disclosure [Abstract]

Debt

Note 6 – Debt

Our long-term debt consists of notes payable associated with our 2021 Term Loan, 2018 Notes and Paycheck Protection Program, each of which is described in further detail below. Long-term notes payable were as follows (in thousands):

	June 30, 2021			December 31, 2020
2021 Term Loan	$	30,000		$	—
2018 Notes		—			24,972
Paycheck Protection Program		3,085			3,107
Other		85			—
Unamortized debt discount and issuance costs		(109	)		(313	)
		33,061			27,766
Less: current maturities		3,106			11,840
Long-term notes payable	$	29,955		$	15,926

2021 Term Loan

On March 19, 2021 (Effective Date), the Company entered into a Loan and Security Agreement (the 2021 Term Loan) by and between Silicon Valley Bank, a California corporation (SVB or Lender) and the Company, as borrower, whereby subject to the terms and conditions of the 2021 Term Loan, SVB advanced to the Company an original principal amount of $30 million.

The 2021 Term Loan provides for an “interest-only” period from the Effective Date through February 28, 2023, with interest due and payable monthly on the first calendar day of each month. However, the Company achieved a revenue milestone of at least $65 million on a trailing twelve-month basis during the three months ended March 31, 2021 which automatically extended the interest-only period through February 28, 2024. Beginning on the first calendar day of the month following the end of the interest-only period, the 2021 Term Loan shall be payable in (i) consecutive equal installments of principal through March 1, 2026, plus (ii) monthly payments of accrued interest. The principal amount outstanding under the 2021 Term Loan shall accrue interest at a floating per annum rate equal to the greater of (i) 2.00% above the prime rate, or (ii) 5.25%, which interest, in each case, shall be payable monthly. Changes to the interest rate applicable to the 2021 Loan based on changes to the prime rate shall be effective on the effective date of any change to the prime rate.

The Company’s final payment, due at maturity on March 1, 2026, shall include all outstanding principal and accrued and unpaid interest, lender fees and expenses, of which the majority will include a final payment of $2.4 million, and all other sums, if any, that shall have become due and payable hereunder with respect to the 2021 Term Loan. The $2.4 million final payment will be amortized as interest expense over the term of the loan. The Company has the option to prepay, prior to maturity, the total outstanding principal amount plus

accrued and unpaid interest, subject to a prepayment penalty of 3% of the principal amount if paid prior to the first anniversary of the Effective Date, 2% of the principal amount if paid on or after the first anniversary but prior to the second anniversary of the Effective Date, 1% of the principal amount if paid on or after the second anniversary but prior to October 19, 2025, and 0% thereafter.

The Company granted the Lender a security interest in substantially all of the Company’s assets. The 2021 Term Loan requires the Company to comply with a minimum liquidity ratio covenant (as defined) by the 2021 Term Loan of not less than 0.95 to 1.00, and has a trailing six month rolling minimum revenue requirement of not less than 70% of the Company’s projected revenue for each such quarter. In addition, the 2021 Term Loan contains certain covenants limiting the ability of the Company to, among other things, incur future debt, transfer assets except for the ordinary course of business, make acquisitions, pay dividends or make other certain restricted payments, or sell assets, subject to certain exceptions, without the prior written consent of the Lender. Failure to comply with the covenants and loan requirements may result in an event of default. As of June 30, 2021, the Company was in compliance with all restrictive and financial covenants associated with its borrowings. In the event of a default, including, among other things, our failure to make any payment when due or our failure to comply with any covenant under the 2021 Term Loan, the Lender may elect to declare all amounts outstanding to be immediately due and payable, and may proceed against the collateral granted to them to secure such indebtedness, including a royalty-free license or other right to use all of our intellectual property without charge.

2018 Notes

In February 2018, the Company issued long-term debt of $23.0 million to Innovatus Life Sciences Lending Fund (Innovatus or Lender) (the 2018 Notes). Innovatus is also a holder of the Company’s common stock.

At the time of issuance, the Company paid a facility fee of $0.2 million and issued a warrant to Innovatus, with an initial estimated fair value of $0.3 million, for the purchase of 613,333 shares of Series G preferred stock. The facility fee and the estimated warrant fair value were recorded as debt discount and is amortized to interest expense over the term of the 2018 Notes. The 2018 Notes bore annual interest at 10%, of which 7.5% was payable in cash, with the remaining 2.5% added to principal through December 31, 2020. Total interest added to principal was $1.7 million as of March 31, 2021 and December 31, 2020.

On March 19, 2021, in connection with entering into the 2021 Term Loan agreement with SVB, the Company repaid all outstanding principal, accrued and unpaid interest, and prepayment fees in the amount of $25.9 million due under the 2018 Notes and contemporaneously terminated the related Loan and Security Agreement, dated as of February 23, 2018, as amended, between Innovatus and the Company. As a result of the extinguishment of the 2018 Notes, the Company recognized a loss on debt extinguishment of $0.7 million during the three months ended March 31, 2021.

Paycheck Protection Program Note Payable

In April 2020, the Company entered into a loan pursuant to the Paycheck Protection Program under the CARES Act, as administered by the U.S. Small Business Administration (the SBA). The loan, in the principal amount of $3.1 million (the PPP Loan), was disbursed by JPMorgan Chase Bank (JPM) pursuant to a Paycheck Protection Program Promissory Note and Agreement (the Note and Agreement).

The PPP Loan matures on the two-year anniversary of the funding date, April 2022, and bears interest at a fixed rate of 1.00% per annum. Monthly principal and interest payments, less the amount of any potential forgiveness (as discussed below), will commence in September 2021. The Company did not provide any collateral or guarantees in connection with the PPP Loan, nor did the Company pay any facility charge to obtain the PPP Loan. The Note and Agreement provides for customary events of default, including those relating to failure to make payment, bankruptcy, breaches of representations and material adverse effects. The Company may prepay the principal of the PPP Loan at any time without incurring any prepayment charges.

All or a portion of the PPP Loan may be forgiven by the SBA upon application by the Company. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, and covered utilities during the eight-week period beginning on the approval date of the PPP Loan. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee earning more than $100,000, prorated annually. Not more than 40% of the forgiven amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages for employees with salaries of $100,000 or less annually are reduced by more than 25%. During the second quarter 2021, the Company determined that it would apply for forgiveness under the SBA’s Loan Forgiveness program, a change from its previous intent to repay. Subsequently, in July 2021 the Company applied for loan forgiveness. The Company has performed initial calculations for the PPP loan forgiveness according to the terms and conditions of the SBA’s Loan Forgiveness Application and, based on such calculations, expects that the PPP loan will be forgiven in full. The Company cannot currently provide any objective assurance that it will obtain forgiveness in whole or in part. If the loan is forgiven in whole or in part, and legal release is received, the Company will reduce the liability by the amount forgiven and record a gain on extinguishment in the statements of operations.

Scheduled principal repayments (maturities) of long-term obligations were as follows (in thousands):

	As of
	June 30, 2021
Remainder of 2021	$	691
2022		2,423
2023		15
2024		13,217
2025		14,418
2026 and thereafter		2,406
Total	$	33,170

Cash paid for interest was $0.7 million and $0.9 million for the six months ended June 30, 2021 and 2020, respectively.

Convertible Preferred Stock

6 Months Ended

Jun. 30, 2021

Class Of Stock Disclosures [Abstract]

Convertible Preferred Stock

Note 7 - Convertible Preferred Stock

Prior to its initial public offering in October 2020, the Company had issued convertible preferred stock from time to time to fund its operations and to make acquisitions. The Company’s convertible preferred stock was reported as temporary equity in the Company’s balance sheet because the preferred shareholders held a majority of the Company’s Board of Directors seats and as a result could have caused certain events to occur outside of the Company’s control, with the result the Company could have been obligated to redeem the convertible preferred stock.

Immediately prior to the Company’s initial public offering and as of June 30, 2020, the Company had issued 118,766,273 convertible preferred shares. On October 27, 2020, upon closing of the Company’s initial public offering, each outstanding share of Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock automatically converted into 0.1684664 share of common stock; and each share of Series B-1 Preferred Stock automatically converted into 0.196 shares of common stock. In the aggregate, all series of preferred stock were converted into 20,090,745 shares of common stock. Subsequent to the Company’s initial public offering, there are no longer any series of convertible preferred stock outstanding.

Warrants to Purchase Convertible Preferred Stock

6 Months Ended

Jun. 30, 2021

Warrants And Rights Note Disclosure [Abstract]

Warrants to Purchase Convertible Preferred Stock

Note 8 – Warrants to Purchase Convertible Preferred Stock

The Company issued warrants to purchase shares of convertible preferred stock in conjunction with the sale of certain of the convertible preferred shares and issuance of debt. As of June 30, 2020 and through the closing of the Company’s initial public offering in October 2020, the preferred warrants were classified as liabilities with estimated fair value remeasured at each reporting date reported within in the accompanying statements of operations.

The following table presents the activity for convertible preferred stock warrants outstanding as of June 30, 2020 (in thousands, except weighted average exercise price):

	Series E						Series G ⁽¹⁾
	Warrants			Weighted Average Exercise price			Warrants		Weighted Average Exercise price
Outstanding ‑ January 1, 2020		925		$	5.00			613	$	0.75
Granted		—			—			—		—
Forfeited/canceled		(925	)		(5.00	)		—		—
Exercised		—			—			—		—
Outstanding ‑ June 30, 2020		—			—			613	$	0.75

The warrants to purchase Series E convertible preferred stock were not exercised and expired during the three months ended June 2020.

⁽¹⁾ On October 27, 2020, all convertible preferred stock converted to common stock at the completion of our initial public offering, and as a consequence, the warrants to purchase Series G convertible preferred stock were converted to 103,326 warrants to purchase common stock, which have an expiration date of February 23, 2028. All common stock warrants remain outstanding as of June 30, 2021.

Revenue & Accounts Receivable Credit Concentration

6 Months Ended

Jun. 30, 2021

Revenue From Contract With Customer [Abstract]

Revenue & Accounts Receivable Credit Concentration

Note 9 – Revenue & Accounts Receivable Credit Concentration

The Company’s revenue is generated from (i) diagnostic tests and (ii) assay development and testing services. Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company conducts diagnostic tests and delivers the completed test results to the prescribing physician or patient, as applicable. The fees for diagnostic tests are billed either to a third party such as Medicare, medical facilities, commercial insurance payers, or to the patient. The Company determines the transaction price related to its diagnostic test contracts by considering the nature of the payer and historical price concessions granted to groups of customers. For diagnostic test revenue, the Company estimates the transaction price, which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience, using a portfolio approach. The Company recognizes revenues for diagnostic tests upon delivery of the tests to the physicians requesting the tests or patient, as applicable.

Services revenue consists of on-market tests, pipeline tests, custom diagnostic testing, and other scientific services for a purpose as defined by any individual customer, which is often with biopharmaceutical companies. The performance obligations and related revenue for these sales is defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or other contractually defined milestone(s), to the customer. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s).

Revenues consisted of the following (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Diagnostic tests	$	10,838	$	3,643	$	38,033	$	7,246
Services		1,047		596		2,718		2,089
Total revenue	$	11,885	$	4,239	$	40,751	$	9,335

Deferred Revenue

Deferred revenue consists of cash payments from customers received in advance of delivery. As test results are delivered, the Company recognizes the deferred revenue in ‘Revenues’ in the statements of operations. Of the $3.5 million in ‘Deferred revenue’ recorded in the balance sheet as of December 31, 2020, $1.9 million was recognized in revenues while $0.6 million was primarily reclassed from non-current liabilities during the six months ended June 30, 2021. The ‘Deferred revenue’ of $2.2 million recorded in the balance sheet as of June 30, 2021 is expected to be recognized in revenues over the next twelve months as test results are delivered and services are performed. Non-current deferred revenue of $1.2 million recorded as of June 30, 2021 within ‘Other long-term liabilities’ in the balance sheets represent amounts to be recognized in excess of twelve months from the balance sheet date.

The Company’s customers in excess of 10% of total revenue, and their related revenue as a percentage of total revenue were as follows:

	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
The Big Ten Conference		40	%		—			53	%		—
Centura Healthcare		6	%		28	%		7	%		13	%
Percent of total revenue		46	%		28	%		60	%		13	%

In addition to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for 56% of the Company’s total revenue for both the three and six months ended June 30, 2021 and 60% of total revenue for both the three and six months ended June 30, 2020. The Company is subject to credit risk from its accounts receivable related to services provided to its customers. The Company does not perform evaluations of customers' financial condition and does not require collateral. The Company’s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows:

	As of
	June 30, 2021			December 31, 2020
The Big Ten Conference		44	%		35	%
Centura Healthcare		2	%		24	%
Purdue University		16	%		—
Percent of total accounts receivable		62	%		59	%

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

Share-Based Compensation

6 Months Ended

Jun. 30, 2021

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Share-Based Compensation

Note 10 – Share-Based Compensation

The Company’s share-based compensation awards are issued under the 2020 Equity Incentive Plan (2020 Plan) and the predecessor 2016 Equity Incentive Plan (2016 Plan) and 2006 Equity Incentive Plan (2006 Plan). Any awards that expire or are forfeited under the 2016 Plan or 2006 Plan become available for issuance under the 2020 Plan. As of June 30, 2021, 682,571 shares of common stock remained available for future issuance under the 2020 Plan.

Share-Based Compensation Expense

Pre-tax share-based compensation expense reported in the Company’s statements of operations was (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020⁽¹⁾
Direct costs and expenses	$	18	$	—	$	18	$	—
Research and development		86		11		354		11
Sales, marketing, general and administrative		435		44		1,919		44
Total	$	539	$	55	$	2,291	$	55

⁽¹⁾	Includes the reversal of performance condition option expense during the three months ended March 31, 2020.

Stock Option Activity

Stock option activity during the six months ended June 30, 2021, excluding the Bonus Option Program described below, was (in thousands, except weighted average exercise price and weighted average contractual life):

	Number of Options			Weighted Average Exercise Price		Weighted Average Contractual Life (Years)		Aggregate Intrinsic Value
Outstanding ‑ January 1, 2021		2,321		$	1.82		7.4	$	42,580
Granted		1,041			19.39		9.7		—
Forfeited/canceled		(122	)		3.64		—		—
Exercised		(366	)		1.43		—		—
Outstanding ‑ June 30, 2021		2,874		$	8.17		8.1	$	20,806
Exercisable - June 30, 2021		1,267		$	4.89		6.9	$	11,778

Restricted Stock Units and Restricted Stock Activity

As of June 30, 2021, there were 119,192 restricted stock units outstanding, with a weighted average grant date fair value of $5.13 per share.

The remaining unrecognized stock‑based compensation expense for options and RSUs was approximately $9.3 million as of June 30, 2021, and is expected to be amortized to expense over the next 4.0 years.

Bonus-to-Options Program

As of June 30, 2021, there were 403,052 options outstanding under the Bonus-to-Options Program (Bonus Option Program) with a remaining weighted average contractual life of 8.0 years. These options are fully-vested and have a weighted average exercise price of $17.30 per share and an intrinsic value of approximately $0.8 million as of June 30, 2021. During the six months ended June 30, 2021, 265,615 options with a weighted average exercise price of $20.67, and the Company received $155,296 of proceeds upon the exercise of 21,712 options. The Company accrued $0.1 million and $0.7 million during the three and six months ended June 30, 2021 related to the estimate of the 2021 Bonus Option Program. Options granted, if any, pertaining to the performance of the Bonus Option Program are typically approved and granted in first quarter of the year following completion of the fiscal year.

Employee Stock Purchase Plan

A total of 338,106 shares of our common stock have been reserved for issuance under the Employee Stock Purchase Plan (ESPP). The initial offering period began January 1, 2021 and continues through August 31, 2021. As of June 30, 2021, no shares have been issued under the ESPP.

Earnings per Share

6 Months Ended

Jun. 30, 2021

Earnings Per Share [Abstract]

Earnings per Share

Note 11 – Earnings Per Share

Basic earnings per share (EPS) excludes dilution and is computed by dividing net loss attributable to the Company’s stockholders by the weighted-average shares outstanding during the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised, resulting in the issuance of shares of common stock that would then share in the earnings or losses of the Company. The number of common shares issuable upon assumed conversion of convertible debt was based on the Company’s estimated common stock price as of June 30, 2020 as determined by the Company’s Board of Directors with assistance from a valuation firm.

In connection with the acquisition of Indi in 2018, the Company recorded contingent consideration (See Note 4 – Fair Value) for amounts contingently payable to Indi's selling shareholders pursuant to the terms of the asset purchase agreement. The contingent consideration arrangement requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month gross margin target of $2.0 million within the seven-year period after the acquisition date. If the gross margin target is met, the Company is required to issue 2,520,108 shares of common stock. The Company met the gross margin target of $2.0 million for three consecutive months during the three months ended June 30, 2021. As a result of the achievement of the gross margin target, the Company included the 2,520,108 shares of common stock in the calculation of weighted-average shares outstanding used in computing basic and diluted net loss per share for the three and six months ended June 30, 2021. In August 2021, the Company entered into an amendment of the original agreement in which the Company has agreed to forgo the issuance of common stock. Therefore, these shares are not included in the statements of convertible preferred stock and stockholders' equity (deficit) or shares issued and outstanding in the balance sheets.

Basic and diluted loss per share for the three and six months ended June 30, 2021 and 2020 were (in thousands, except per share amounts):

	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
Numerator
Net loss attributable to common stockholders	$	(11,402	)	$	(8,266	)	$	(18,363	)	$	(17,971	)

Denominator
Weighted-average shares outstanding used in computing net loss per share, basic and diluted		27,730			275			27,020			261
Net loss per share, basic and diluted	$	(0.41	)	$	(30.06	)		(0.68	)		(68.85	)

The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Options to purchase common stock		2,874		2,813		2,874		2,813
Convertible preferred stock		—		119,257		—		119,257
Warrants		103		613		103		613
Restricted stock units		119		53		119		53
Convertible debt		—		42,771		—		42,771
Total		3,096		165,507		3,096		165,507

Income Taxes

6 Months Ended

Jun. 30, 2021

Income Tax Disclosure [Abstract]

Income Taxes

Note 12 - Income Taxes

Since inception, the Company has incurred net taxable losses, and accordingly, no provision for income taxes has been recorded. There was no cash paid for income taxes during the three and six months ended June 30, 2021 and 2020.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Commitments and Contingencies

6 Months Ended

Jun. 30, 2021

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 13 – Commitments and Contingencies

Leases

The Company leases facilities under non‑cancelable operating leases. Rent expense was $0.3 million and $0.6 million for the three and six months ended June 30, 2021, respectively, and $0.5 million and $1.1 million for the three and six months ended June 30, 2020, respectively.

Future minimum lease payments for operating lease obligations are as follows (in thousands):

	As of
	June 30, 2021
Remainder of 2021	$	352
2022		724
2023		112
Total	$	1,188

Co‑Development Agreement

In April 2014 and amended in October 2016, the Company entered into a worldwide agreement with AVEO to develop and commercialize AVEO's hepatocyte growth factor inhibitory antibody ficlatuzumab with the Company's proprietary companion diagnostic test, BDX004, a version of the Company’s serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO will conduct a proof of concept (POC) clinical study of ficlatuzumab for NSCLC in which BDX004 will be used to select clinical trial subjects (the NSCLC POC Trial). The Company and AVEO will share equally in the costs of the NSCLC POC Trial, and each will be responsible for 50% of development and regulatory costs associated with all future clinical trials agreed upon by the Company and AVEO. The Company and AVEO continue to conduct POC clinical trials of ficlatuzumab in combination with BDX004 with each responsible for 50% of development and regulatory costs.

In September 2020, the Company exercised its opt-out right with AVEO for the payment of 50% of development and regulatory costs for ficlatuzumab effective December 2, 2020. The Company had $0.3 million in remaining obligations related to the AVEO agreement as of June 30, 2021. Following the effective date, the Company is entitled to a 10% royalty of net sales of ficlatuzumab and 25% of license income generated from the licensing of ficlatuzumab from AVEO.

There were no expenses related to this agreement for the three and six months ended June 30, 2021. Expenses related to this agreement for the three and six months ended June 30, 2020 were $0.1 million and $0.7 million, respectively.

License Agreements

In August 2019, we entered into a non-exclusive license agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) (the Bio-Rad License). Under the terms of the Bio-Rad License, the Company received a non-exclusive license, without the right to grant sublicenses, to utilize certain of Bio-Rad’s intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of Droplet Digital PCR™ (ddPCR) in cancer detection testing for third parties in the United States. The Company also agreed to purchase all of the necessary supplies and reagents for such testing exclusively from Bio-Rad, pursuant to a separately executed supply agreement (the Supply Agreement) with Bio-Rad. As further consideration for the non-exclusive license, the Company agreed to pay a royalty of 2.5% on the net revenue received for the performance of such ddPCR testing collected from third parties. On May 24, 2021, the Company entered into the First Amendment to the Non-Exclusive License Agreement with Bio-Rad which amended the Bio-Rad License such that, effective May 1, 2021, the Company will no longer pay a royalty of 2.5% on the net revenue received for the performance of such ddPCR testing collected from third parties. The Bio-Rad License expires in August 2024. Either party may terminate for the other’s uncured material breach or bankruptcy events. Bio-Rad may terminate the Bio-Rad License if the Company does not purchase licensed products under the Supply Agreement for a consecutive twelve-month period or for any material breach by us of the Supply Agreement. Royalty expense under the Bio-Rad License for the three and six months ended June 30, 2021 and 2020 were not significant.

On May 13, 2021 (Effective Date), we reached agreement with CellCarta Biosciences Inc. (formerly “Caprion Biosciences, Inc.”) (the CellCarta License) on a new royalty bearing license agreement for the Nodify XL2 test. The parties agreed to terminate all prior agreements and replace with this new arrangement, which has a 1% fee on net sales made from the first commercial sale of the Nodify XL2 test to the Effective Date as an upfront make-good payment covering past royalties due and a royalty rate of 0.675% on future Nodify XL2 net sales worldwide for 15 years from the first commercial sale, ending in 2034. Royalty expense under the CellCarta License for the three and six months ended June 30, 2021 was $0.1 million.

Revenue Share Agreement

As part of the acquisition of the assets of Oncimmune USA, the Company entered into several agreements to govern the relationship between the parties. The Company agreed to a revenue share payment related to an acquired diagnostic test of 8% of recognized revenue for non-screening tests up to an annual minimum volume and 5% thereafter, with an escalating minimum through the first four years of sales. Revenue share expenses of $0.1 million and $0.3 were incurred for the three and six months ended June 30, 2021, respectively, and $0.1 million and $0.2 million for the three and six months ended June 30, 2020, respectively.

Litigation, Claims and Assessments

From time to time, we may become involved in legal proceedings or investigations which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition, or cash flows.

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

Basis of Presentation

Use of Estimates

Concentration of Credit Risk and Other Uncertainties

For a discussion of credit risk concentration of accounts receivable as of June 30, 2021 and 2020, see Note 9 – Revenue & Accounts Receivable Credit Concentration.

Inventory

Fair Value of Financial Instruments

Level		Inputs
1		Unadjusted quoted prices in active markets for identical assets and liabilities.
2		Unadjusted quoted prices in active markets for similar assets and liabilities;
		Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or
		Inputs other than quoted prices that are observable for the asset or liability.
3		Unobservable inputs for the asset or liability.

See Note 4 — Fair Value for further discussion related to estimated fair value measurements.

Fair Value (Tables)

6 Months Ended

Jun. 30, 2021

Fair Value Disclosures [Abstract]

Summary of Fair Value of Outstanding Borrowings

The fair values of outstanding borrowings, which are classified as Level 2, approximate their carrying values as of June 30, 2021 and December 31, 2020, based on interest rates currently available for similar borrowings and were (in thousands):

	As of
	June 30, 2021				December 31, 2020
	Carrying Value		Fair Value		Carrying Value		Fair Value
Borrowings	$	33,061	$	33,061	$	27,766	$	27,766

Schedule of Reported Fair values of Contingent Consideration

The table below presents the reported fair values of contingent consideration, which is classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands):

Description	June 30, 2021		December 31, 2020
Current portion of contingent consideration	$	8,626	$	—
Contingent consideration		23,217		29,932
Total contingent consideration	$	31,843	$	29,932

Schedule of Changes in Contingent Consideration and Financial Liabilities

The following table presents the changes in contingent consideration for the six months ended June 30, 2021 (in thousands):

Level 3 Rollforward	For the Six Months Ended June 30, 2021
Beginning balances - January 1, 2021	$	29,932
Changes in fair value		1,622
Interest expense		289
Ending balances - June 30, 2021	$	31,843

The following table presents the changes in these financial liabilities for the six months ended June 30, 2020 (in thousands):

	For the Six Months Ended June 30, 2020
Level 3 Rollforward	Contingent Consideration		Put Option Liability		Warrant Liability			Contingent Value Rights
Beginning balances - January 1, 2020	$	29,114	$	3,261	$	372		$	60
Additions		—		3,340		—			—
Changes in fair value		—		—		(55	)		—
Ending balances - June 30, 2020	$	29,114	$	6,601	$	317		$	60

Supplementary Balance Sheet Information (Tables)

6 Months Ended

Jun. 30, 2021

Balance Sheet Related Disclosures [Abstract]

Schedule of Property and Equipment

Property and equipment consist of the following (in thousands):

	June 30, 2021			December 31, 2020
Lab equipment	$	6,197		$	5,730
Leasehold improvements		2,032			1,845
Computer equipment		871			871
Furniture and fixtures		424			424
Software		655			651
Vehicles		97			—
Construction in process		195			381
		10,471			9,902
Less: accumulated depreciation		(7,093	)		(6,724	)
Total property and equipment, net	$	3,378		$	3,178

Schedule of Intangible Assets, Excluding Goodwill

Intangible assets, excluding goodwill, consist of the following (in thousands):

	June 30, 2021							December 31, 2020
	Cost		Accumulated Amortization			Net Carrying Value		Cost		Accumulated Amortization			Net Carrying Value
Intangible assets subject to amortization
Patents	$	1,590	$	(533	)	$	1,057	$	1,474	$	(494	)	$	980
Purchased technology		16,900		(5,633	)		11,267		16,900		(4,694	)		12,206
Intangible assets not subject to amortization
Trademarks		76		—			76		74		—			74
Total	$	18,566	$	(6,166	)	$	12,400	$	18,448	$	(5,188	)	$	13,260

Schedule of Future Estimated Amortization Expense of Intangible Assets

	As of
	June 30, 2021
Remainder of 2021	$	976
2022		1,951
2023		1,947
2024		1,940
2025		1,936
2026 and thereafter		3,574
Total	$	12,324

Schedule of Accrued Liabilities

Accrued liabilities consist of the following (in thousands):

	June 30, 2021		December 31, 2020
Compensation related accruals	$	2,117	$	3,975
Accrued clinical trial expense		842		715
Other expenses		3,239		3,099
Total accrued liabilities	$	6,198	$	7,789

Debt (Tables)

6 Months Ended

Jun. 30, 2021

Debt Disclosure [Abstract]

Summary of Long-term Notes Payable

Long-term notes payable were as follows (in thousands):

	June 30, 2021			December 31, 2020
2021 Term Loan	$	30,000		$	—
2018 Notes		—			24,972
Paycheck Protection Program		3,085			3,107
Other		85			—
Unamortized debt discount and issuance costs		(109	)		(313	)
		33,061			27,766
Less: current maturities		3,106			11,840
Long-term notes payable	$	29,955		$	15,926

Scheduled Principal Repayments (Maturities) of Long-term Obligations

Scheduled principal repayments (maturities) of long-term obligations were as follows (in thousands):

	As of
	June 30, 2021
Remainder of 2021	$	691
2022		2,423
2023		15
2024		13,217
2025		14,418
2026 and thereafter		2,406
Total	$	33,170

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Warrants to Purchase Convertible Preferred Stock (Tables)

6 Months Ended

Jun. 30, 2021

Warrants And Rights Note Disclosure [Abstract]

Summary of Activity for Convertible Preferred Stock Warrants Outstanding

The following table presents the activity for convertible preferred stock warrants outstanding as of June 30, 2020 (in thousands, except weighted average exercise price):

	Series E						Series G ⁽¹⁾
	Warrants			Weighted Average Exercise price			Warrants		Weighted Average Exercise price
Outstanding ‑ January 1, 2020		925		$	5.00			613	$	0.75
Granted		—			—			—		—
Forfeited/canceled		(925	)		(5.00	)		—		—
Exercised		—			—			—		—
Outstanding ‑ June 30, 2020		—			—			613	$	0.75

Revenue & Accounts Receivable Credit Concentration (Tables)

6 Months Ended

Jun. 30, 2021

Revenue From Contract With Customer [Abstract]

Summary of Revenue

Revenues consisted of the following (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Diagnostic tests	$	10,838	$	3,643	$	38,033	$	7,246
Services		1,047		596		2,718		2,089
Total revenue	$	11,885	$	4,239	$	40,751	$	9,335

Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers

The Company’s customers in excess of 10% of total revenue, and their related revenue as a percentage of total revenue were as follows:

	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
The Big Ten Conference		40	%		—			53	%		—
Centura Healthcare		6	%		28	%		7	%		13	%
Percent of total revenue		46	%		28	%		60	%		13	%

The Company’s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows:

	As of
	June 30, 2021			December 31, 2020
The Big Ten Conference		44	%		35	%
Centura Healthcare		2	%		24	%
Purdue University		16	%		—
Percent of total accounts receivable		62	%		59	%

Share-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2021

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Pre-tax Share-based Compensation Expense

Share-Based Compensation Expense

Pre-tax share-based compensation expense reported in the Company’s statements of operations was (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020⁽¹⁾
Direct costs and expenses	$	18	$	—	$	18	$	—
Research and development		86		11		354		11
Sales, marketing, general and administrative		435		44		1,919		44
Total	$	539	$	55	$	2,291	$	55

⁽¹⁾	Includes the reversal of performance condition option expense during the three months ended March 31, 2020.

Summary of Stock Option Activity

	Number of Options			Weighted Average Exercise Price		Weighted Average Contractual Life (Years)		Aggregate Intrinsic Value
Outstanding ‑ January 1, 2021		2,321		$	1.82		7.4	$	42,580
Granted		1,041			19.39		9.7		—
Forfeited/canceled		(122	)		3.64		—		—
Exercised		(366	)		1.43		—		—
Outstanding ‑ June 30, 2021		2,874		$	8.17		8.1	$	20,806
Exercisable - June 30, 2021		1,267		$	4.89		6.9	$	11,778

Earnings per Share (Tables)

6 Months Ended

Jun. 30, 2021

Earnings Per Share [Abstract]

Schedule of Computation of Basic and Diluted Loss per Share Attributable to Stockholders

Basic and diluted loss per share for the three and six months ended June 30, 2021 and 2020 were (in thousands, except per share amounts):

	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
Numerator
Net loss attributable to common stockholders	$	(11,402	)	$	(8,266	)	$	(18,363	)	$	(17,971	)

Denominator
Weighted-average shares outstanding used in computing net loss per share, basic and diluted		27,730			275			27,020			261
Net loss per share, basic and diluted	$	(0.41	)	$	(30.06	)		(0.68	)		(68.85	)

Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders

	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Options to purchase common stock		2,874		2,813		2,874		2,813
Convertible preferred stock		—		119,257		—		119,257
Warrants		103		613		103		613
Restricted stock units		119		53		119		53
Convertible debt		—		42,771		—		42,771
Total		3,096		165,507		3,096		165,507

Commitments and Contingencies (Tables)

6 Months Ended

Jun. 30, 2021

Commitments And Contingencies Disclosure [Abstract]

Summary of Future Minimum Lease Payments for Operating Lease Obligations

Future minimum lease payments for operating lease obligations are as follows (in thousands):

	As of
	June 30, 2021
Remainder of 2021	$	352
2022		724
2023		112
Total	$	1,188

Organization and Description of Business - Additional Information (Details)	6 Months Ended
	Jun. 30, 2021 Test
Organization And Description Of Business [Abstract]
Number of blood based lung cancer test	4
Number of commercial blood-based test	2
Number of SARS-CoV-2 test	3

Summary of Significant Accounting Policies - Additional Information (Details) - Other Current Assets - USD ($) $ in Millions	Jun. 30, 2021	Dec. 31, 2020
Summary Of Significant Accounting Policies [Line Items]
Restricted cash	$ 0.1	$ 0.2
Inventory	$ 3.1	$ 3.2

Fair Value - Summary of Fair Value of Outstanding Borrowings (Details) - Fair Value, Recurring - Level 2 - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Carrying Value
Fair Value Liabilities Measured On Recurring Basis [Line Items]
Borrowings	$ 33,061	$ 27,766
Fair Value
Fair Value Liabilities Measured On Recurring Basis [Line Items]
Borrowings	$ 33,061	$ 27,766

Fair Value - Schedule of Reported Fair values of Contingent Consideration (Details) - Fair Value, Recurring - Level 3 - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Fair Value Liabilities Measured On Recurring Basis [Line Items]
Total contingent consideration	$ 31,843	$ 29,932
Current Portion of Contingent Consideration
Fair Value Liabilities Measured On Recurring Basis [Line Items]
Total contingent consideration	8,626
Contingent Consideration
Fair Value Liabilities Measured On Recurring Basis [Line Items]
Total contingent consideration	$ 23,217	$ 29,932

Fair Value - Schedule of Changes in Contingent Consideration (Details) - Fair Value, Recurring - Level 3 - Contingent Consideration - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balances	$ 29,932	$ 29,114
Changes in fair value	1,622
Interest expense	289
Ending balances	$ 31,843	$ 29,114

Fair Value - Schedule of Changes in Financial Liabilities (Details) - Fair Value, Recurring - Level 3 - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Contingent Consideration
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balances	$ 29,932	$ 29,114
Changes in fair value	1,622
Ending balances	$ 31,843	29,114
Put Option Liability
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balances		3,261
Additions		3,340
Ending balances		6,601
Warrant Liability
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balances		372
Changes in fair value		(55)
Ending balances		317
Contingent Value Rights
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balances		60
Ending balances		$ 60

Fair Value - Additional Information (Details) $ / shares in Units, $ in Thousands		1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 19, 2021 USD ($)	Sep. 30, 2020	Jan. 31, 2016 USD ($) shares	Jun. 30, 2021 USD ($) Installment $ / shares shares	Jun. 30, 2020 USD ($)	Jun. 30, 2021 USD ($) Installment $ / shares shares	Jun. 30, 2020 USD ($)	Dec. 31, 2018 USD ($) Installment shares	Feb. 28, 2018 USD ($) shares
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Net change to contingent consideration						$ 1,622
Put option liability					$ 3,300		$ 3,300
Warrants, expires period				Feb. 23, 2028		Feb. 23, 2028
Estimated air value of warrants issued				$ 300		$ 300
Change in fair value of warrant liability					4		55
Initial Public Offering
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant, exercise price \| $ / shares				$ 4.46		$ 4.46
Warrant issued to purchase shares \| shares				103,326		103,326
Series F Preferred Stock
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent value rights shares \| shares			3,999
Contingent value rights			$ 500
Contingent value rights percentage			0.00375%
Net proceeds percentage of cash payment to the CVR holders			15.00%
Series F Preferred Stock \| AVEO Oncology
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of development and regulatory costs exercised using opt-out right		50.00%
2018 Notes
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Repayments of Debt	$ 25,900
Estimated air value of warrants issued									$ 300
2018 Notes \| Series G Preferred Stock
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant issued to purchase shares \| shares				613,333		613,333			613,333
Warrant, exercise price \| $ / shares				$ 0.75		$ 0.75
Operating Expense
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Net change to contingent consideration				$ 600	$ (1,000)	$ 1,600	$ 0
Interest Expense
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Net change to contingent consideration				300		$ 300
Integrated Diagnostics, Inc
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business acquisition description						requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month
Business acquisition contingent consideration gross margin target				$ 2,000				$ 2,000
Business acquisition contingent consideration gross margin target period								7 years
Integrated Diagnostics, Inc \| Common Stock
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business acquisition description						If Indi elects to not exercise its option, the Company has 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million.
Contingent consideration shares \| shares								2,520,108
Contingent consideration number of installments \| Installment				6		6		8
Contingent consideration arrangements, common shares, redemption amount						$ 4,600		$ 37,000
Repayments of Debt						9,300
Business combination contingent consideration final payment						$ 37,000
Integrated Diagnostics, Inc \| Common Stock \| Repurchase
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration number of installments \| Installment								2
Contingent consideration cash payment								$ 37,000
Minimum
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range						11.00%
Maximum
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range						13.50%

Supplementary Balance Sheet Information - Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 10,471	$ 9,902
Less: accumulated depreciation	(7,093)	(6,724)
Total property and equipment, net	3,378	3,178
Lab Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	6,197	5,730
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	2,032	1,845
Computer Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	871	871
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	424	424
Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	655	651
Vehicles
Property Plant And Equipment [Line Items]
Property and equipment, gross	97
Construction in Process
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 195	$ 381

Supplementary Balance Sheet Information - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Balance Sheet Related Disclosures [Abstract]
Depreciation expense	$ 0.2	$ 0.2	$ 0.5	$ 0.4
Amortization expense of definite-lived intangible assets	$ 0.5	$ 0.5	$ 1.0	$ 1.0

Supplementary Balance Sheet Information - Intangible Assets, Excluding Goodwill (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Finite Lived Intangible Assets [Line Items]
Intangible assets subject to amortization, Net Carrying Value	$ 12,324
Intangible assets, Cost	18,566	$ 18,448
Intangible assets, Accumulated Amortization	(6,166)	(5,188)
Intangible assets, Net Carrying Value	12,400	13,260
Trademarks
Finite Lived Intangible Assets [Line Items]
Intangible assets not subject to amortization, Cost	76	74
Intangible assets not subject to amortization, Net Carrying Value	76	74
Patents
Finite Lived Intangible Assets [Line Items]
Intangible assets subject to amortization, Cost	1,590	1,474
Intangible assets subject to amortization, Accumulated Amortization	(533)	(494)
Intangible assets subject to amortization, Net Carrying Value	1,057	980
Purchased Technology
Finite Lived Intangible Assets [Line Items]
Intangible assets subject to amortization, Cost	16,900	16,900
Intangible assets subject to amortization, Accumulated Amortization	(5,633)	(4,694)
Intangible assets subject to amortization, Net Carrying Value	$ 11,267	$ 12,206

Supplementary Balance Sheet Information - Schedule of Amortization Related to Remaining Net Intangible Assets Schedule to Amortize (Details) $ in Thousands	Jun. 30, 2021 USD ($)
Balance Sheet Related Disclosures [Abstract]
Remainder of 2021	$ 976
2022	1,951
2023	1,947
2024	1,940
2025	1,936
2026 and thereafter	3,574
Intangible assets subject to amortization, Net Carrying Value	$ 12,324

Supplementary Balance Sheet Information - Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Compensation related accruals	$ 2,117	$ 3,975
Accrued clinical trial expense	842	715
Other expenses	3,239	3,099
Total accrued liabilities	$ 6,198	$ 7,789

Debt - Summary of Long-term Notes Payable (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Mar. 19, 2021	Dec. 31, 2020	Apr. 30, 2020	Feb. 28, 2018
Debt Instrument [Line Items]
Unamortized debt discount and issuance costs	$ (109)		$ (313)
Notes payable, total	33,061		27,766
Less: current maturities	3,106		11,840
Long-term notes payable	29,955		15,926
2021 Term Loan
Debt Instrument [Line Items]
Notes/Loan payable	30,000	$ 30,000
2018 Notes
Debt Instrument [Line Items]
Notes/Loan payable			24,972		$ 23,000
PPP Loan \| CARES Act
Debt Instrument [Line Items]
Notes/Loan payable	3,085		$ 3,107	$ 3,100
Other
Debt Instrument [Line Items]
Notes/Loan payable	$ 85

Debt - Additional Information (Details) - USD ($)		1 Months Ended	3 Months Ended	6 Months Ended
Debt - Additional Information (Details) - USD ($)	Mar. 19, 2021	Apr. 30, 2020	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Feb. 28, 2018
Debt Instrument [Line Items]
Estimated air value of warrants issued				$ 300,000
Loss on debt extinguishment				(728,000)
Cash paid for interest				700,000	$ 900,000
2021 Term Loan
Debt Instrument [Line Items]
Notes/Loan payable	$ 30,000,000			$ 30,000,000
Debt instrument frequency of periodic payment	monthly
Revenue milestone			$ 65,000,000
Debt instrument description				The 2021 Term Loan provides for an “interest-only” period from the Effective Date through February 28, 2023, with interest due and payable monthly on the first calendar day of each month. However, the Company achieved a revenue milestone of at least $65 million on a trailing twelve-month basis during the three months ended March 31, 2021 which automatically extended the interest-only period through February 28, 2024. Beginning on the first calendar day of the month following the end of the interest-only period, the 2021 Term Loan shall be payable in (i) consecutive equal installments of principal through March 1, 2026, plus (ii) monthly payments of accrued interest. The principal amount outstanding under the 2021 Term Loan shall accrue interest at a floating per annum rate equal to the greater of (i) 2.00% above the prime rate, or (ii) 5.25%, which interest, in each case, shall be payable monthly. Changes to the interest rate applicable to the 2021 Loan based on changes to the prime rate shall be effective on the effective date of any change to the prime rate.
Debt instrument maturity date	Mar. 01, 2026
Repayments of Debt	$ 2,400,000
Debt instrument, covenant description				The 2021 Term Loan requires the Company to comply with a minimum liquidity ratio covenant (as defined) by the 2021 Term Loan of not less than 0.95 to 1.00, and has a trailing six month rolling minimum revenue requirement of not less than 70% of the Company’s projected revenue for each such quarter.
Debt instrument, covenant compliance				the Company was in compliance with all restrictive and financial covenants associated with its borrowings.
Loan principle amount	$ 30,000,000			$ 30,000,000
2021 Term Loan \| Prior to First Anniversary
Debt Instrument [Line Items]
Debt instrument, prepayment penalty	3.00%
2021 Term Loan \| Prior to Second Anniversary
Debt Instrument [Line Items]
Debt instrument, prepayment penalty	2.00%
2021 Term Loan \| After Second Anniversary, Prior to October 19, 2025
Debt Instrument [Line Items]
Debt instrument, prepayment penalty	1.00%
2021 Term Loan \| Thereafter
Debt Instrument [Line Items]
Debt instrument, prepayment penalty	0.00%
2021 Term Loan \| Maximum
Debt Instrument [Line Items]
Minimum liquidity ratio covenant	0.95
Percentage of minimum revenue requirement	70.00%
2018 Notes
Debt Instrument [Line Items]
Notes/Loan payable						$ 24,972,000	$ 23,000,000.0
Repayments of Debt	$ 25,900,000
Facility fee amount							200,000
Estimated air value of warrants issued							$ 300,000
Interest rate							10.00%
Percentage of interest rate, paid in cash							7.50%
Percentage of interest rate added to principal value of notes payable							2.50%
Interest added to principal value						1,700,000
Loss on debt extinguishment			$ 700,000
Loan principle amount						24,972,000	$ 23,000,000.0
2018 Notes \| Series G Preferred Stock
Debt Instrument [Line Items]
Warrant issued to purchase shares				613,333			613,333
PPP Loan
Debt Instrument [Line Items]
Debt instrument description				The PPP Loan matures on the two-year anniversary of the funding date, April 2022, and bears interest at a fixed rate of 1.00% per annum. Monthly principal and interest payments, less the amount of any potential forgiveness (as discussed below), will commence in September 2021. The Company did not provide any collateral or guarantees in connection with the PPP Loan, nor did the Company pay any facility charge to obtain the PPP Loan.
PPP Loan \| Interest-bearing Deposits
Debt Instrument [Line Items]
Interest rate		1.00%
PPP Loan \| CARES Act
Debt Instrument [Line Items]
Notes/Loan payable		$ 3,100,000		$ 3,085,000		3,107,000
Loan principle amount		$ 3,100,000		$ 3,085,000		$ 3,107,000
Percentage for non-payroll costs		40.00%
Upper limit of employee salary to reduce forgiveness		$ 100,000
Percentage of upper limit of employee salary to reduce forgiveness		25.00%
PPP Loan \| Minimum \| CARES Act
Debt Instrument [Line Items]
Payroll costs excludes compensation of an employee		$ 100,000

Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details) $ in Thousands	Jun. 30, 2021 USD ($)
Maturities Of Long Term Debt [Abstract]
Remainder of 2021	$ 691
2022	2,423
2023	15
2024	13,217
2025	14,418
2026 and thereafter	2,406
Long-term debt	$ 33,170

Convertible Preferred Stock - Additional Information (Details)	Oct. 27, 2020 shares	Jun. 30, 2020 shares
Class Of Stock [Line Items]
Convertible preferred stock, issued		118,766,273
Number of preferred stock converted into common stock	20,090,745
Convertible preferred stock, outstanding	0
Series A-1 Preferred Stock
Class Of Stock [Line Items]
Reverse stock split ratio	0.1684664
Series A2 Preferred Stock
Class Of Stock [Line Items]
Reverse stock split ratio	0.1684664
Series A3 Preferred Stock
Class Of Stock [Line Items]
Reverse stock split ratio	0.1684664
Series B Preferred Stock
Class Of Stock [Line Items]
Reverse stock split ratio	0.1684664
Series C Preferred Stock
Class Of Stock [Line Items]
Reverse stock split ratio	0.1684664
Series D Preferred Stock
Class Of Stock [Line Items]
Reverse stock split ratio	0.1684664
Series E Preferred Stock
Class Of Stock [Line Items]
Reverse stock split ratio	0.1684664
Series F Preferred Stock
Class Of Stock [Line Items]
Reverse stock split ratio	0.1684664
Series G Preferred Stock
Class Of Stock [Line Items]
Reverse stock split ratio	0.1684664
Series H Convertible Preferred Stock
Class Of Stock [Line Items]
Reverse stock split ratio	0.1684664
Series B1 Convertible Preferred Stock
Class Of Stock [Line Items]
Reverse stock split ratio	0.196

Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants Outstanding (Details) shares in Thousands	6 Months Ended
	Jun. 30, 2020 $ / shares shares
Series E Convertible Preferred Stock Warrants
Class Of Warrant Or Right [Line Items]
Outstanding - January 1, 2020, warrants \| shares	925
Forfeited/canceled, warrants \| shares	(925)
Weighted average exercise price, Outstanding - January 1, 2020, warrants \| $ / shares	$ 5.00
Weighted average exercise price, Forfeited/canceled \| $ / shares	$ (5.00)
Series G Convertible Preferred Stock Warrants
Class Of Warrant Or Right [Line Items]
Outstanding - January 1, 2020, warrants \| shares	613
Outstanding - March 31, 2020, warrants \| shares	613
Weighted average exercise price, Outstanding - January 1, 2020, warrants \| $ / shares	$ 0.75
Weighted average exercise price, Outstanding - March 31, 2020, warrants \| $ / shares	$ 0.75

Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants Outstanding (Parenthetical) (Details) - Series G Convertible Preferred Stock Warrants	Oct. 27, 2020 shares
Class Of Warrant Or Right [Line Items]
Warrants to purchase shares of common stock	103,326
Warrants expiration date	Feb. 23, 2028

Revenue & Accounts Receivable Credit Concentration - Summary of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disaggregation Of Revenue [Line Items]
Revenues	$ 11,885	$ 4,239	$ 40,751	$ 9,335
Diagnostic Tests
Disaggregation Of Revenue [Line Items]
Revenues	10,838	3,643	38,033	7,246
Services
Disaggregation Of Revenue [Line Items]
Revenues	$ 1,047	$ 596	$ 2,718	$ 2,089

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

Revenue & Accounts Receivable Credit Concentration - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Disaggregation Of Revenue [Line Items]
Revenue recognized					$ 1,900
Amount reclassified from non-current liabilities			$ 600
Deferred revenue	$ 2,182		$ 2,182		$ 3,532
Revenue \| Customer Concentration Risk
Disaggregation Of Revenue [Line Items]
Concentration risk, percentage	46.00%	28.00%	60.00%	13.00%
Revenue \| Customer Concentration Risk \| Medicare
Disaggregation Of Revenue [Line Items]
Concentration risk, percentage	56.00%	60.00%	56.00%	60.00%
Other Long-term Liabilities
Disaggregation Of Revenue [Line Items]
Non-current deferred revenue	$ 1,200		$ 1,200

Revenue & Accounts Receivable Credit Concentration - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details) - Customer Concentration Risk	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Revenue
Concentration Risk [Line Items]
Concentration risk, percentage	46.00%	28.00%	60.00%	13.00%
Revenue \| The Big Ten Conference
Concentration Risk [Line Items]
Concentration risk, percentage	40.00%		53.00%
Revenue \| Centura Healthcare
Concentration Risk [Line Items]
Concentration risk, percentage	6.00%	28.00%	7.00%	13.00%
Accounts Receivable
Concentration Risk [Line Items]
Concentration risk, percentage			62.00%		59.00%
Accounts Receivable \| The Big Ten Conference
Concentration Risk [Line Items]
Concentration risk, percentage			44.00%		35.00%
Accounts Receivable \| Centura Healthcare
Concentration Risk [Line Items]
Concentration risk, percentage			2.00%		24.00%
Accounts Receivable \| Purdue University
Concentration Risk [Line Items]
Concentration risk, percentage			16.00%

Share-Based Compensation - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of outstanding stock options granted	2,874,000		2,874,000		2,321,000
Weighted average remaining contractual life, outstanding			8 years 1 month 6 days		7 years 4 months 24 days
Intrinsic value	$ 20,806,000		$ 20,806,000		$ 42,580,000
Number of stock options granted			1,041,000
Weighted average exercise price, granted			$ 19.39
Proceeds from exercise of stock options			$ 679,000	$ 11,000
Exercise of stock options, shares			366,000
Stock compensation expense	$ 539,000	$ 55,000	$ 2,291,000	$ 55,000
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares reserved for issuance	338,106		338,106
Shares issued			0
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units outstanding	119,192		119,192
Weighted average grant date fair value	$ 5.13		$ 5.13
Options and Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Remaining unrecognized stock based compensation expense for options and RSUs	$ 9,300,000		$ 9,300,000
Amortized to expense period			4 years
Bonus-To-Options Program
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of outstanding stock options granted	403,052		403,052
Weighted average remaining contractual life, outstanding			8 years
Weighted average exercise price,vested	$ 17.30		$ 17.30
Intrinsic value	$ 800,000		$ 800,000
Number of stock options granted			265,615
Weighted average exercise price, granted			$ 20.67
Proceeds from exercise of stock options			$ 155,296
Exercise of stock options, shares			21,712
Stock compensation expense	$ 100,000		$ 700,000
2020 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock remained available for future issuance	682,571		682,571

Share-Based Compensation - Summary of Pre-tax Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total pre-tax share-based compensation expense	$ 539	$ 55	$ 2,291	$ 55
Direct Costs and Expenses
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total pre-tax share-based compensation expense	18		18
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total pre-tax share-based compensation expense	86	11	354	11
Sales, Marketing, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total pre-tax share-based compensation expense	$ 435	$ 44	$ 1,919	$ 44

Share-Based Compensation - Summary of Stock Option Activity (Details) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Options, Outstanding - January 1, 2021 \| shares	2,321
Stock Options, Granted \| shares	1,041
Stock Options, Forfeited/canceled \| shares	(122)
Stock Options, Exercised \| shares	(366)
Stock Options, Outstanding - June 30, 2021 \| shares	2,874	2,321
Stock Options Exercisable - June 30, 2021 \| shares	1,267
Weighted Average Exercise Price, Outstanding - January 1, 2021 \| $ / shares	$ 1.82
Weighted Average Exercise Price, Granted \| $ / shares	19.39
Weighted Average Exercise Price, Forfeited/canceled \| $ / shares	3.64
Weighted Average Exercise Price, Exercised \| $ / shares	1.43
Weighted Average Exercise Price, Outstanding - June 30, 2021 \| $ / shares	8.17	$ 1.82
Weighted Average Exercise Price, Exercisable - June 30, 2021 \| $ / shares	$ 4.89
Weighted Average Contractual Life (Years), Outstanding - January 1, 2021	8 years 1 month 6 days	7 years 4 months 24 days
Weighted Average Contractual Life (Years), Granted	9 years 8 months 12 days
Weighted Average Contractual Life (Years), Exercisable - June 30, 2021	6 years 10 months 24 days
Aggregate Intrinsic Value, Outstanding - January 1, 2021 \| $	$ 42,580
Aggregate Intrinsic Value, Outstanding - June 30, 2021 \| $	20,806	$ 42,580
Aggregate Intrinsic Value, Exercisable - June 30, 2021 \| $	$ 11,778

Earnings Per Share - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2018
Earnings Per Share Basic [Line Items]
Weighted-average shares outstanding used in computing net loss per share, basic and diluted	27,730,000	275,000	27,020,000	261,000
Integrated Diagnostics, Inc
Earnings Per Share Basic [Line Items]
Business acquisition description			requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month
Business acquisition contingent consideration gross margin target	$ 2.0				$ 2.0
Business acquisition contingent consideration gross margin target period					7 years
Weighted-average shares outstanding used in computing net loss per share, basic and diluted	2,520,108		2,520,108
Integrated Diagnostics, Inc \| Common Stock
Earnings Per Share Basic [Line Items]
Business acquisition description			If Indi elects to not exercise its option, the Company has 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million.
Contingent consideration shares					2,520,108

Earnings per Share - Schedule of Computation of Basic and Diluted Loss per Share Attributable to Stockholders (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Numerator
Net loss attributable to common stockholders	$ (11,402)	$ (6,961)	$ (8,266)	$ (9,705)	$ (18,363)	$ (17,971)
Denominator
Weighted-average shares outstanding, basic and diluted	27,730		275		27,020	261
Net loss per share, basic and diluted	$ (0.41)		$ (30.06)		$ (0.68)	$ (68.85)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Earnings per Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	3,096	165,507	3,096	165,507
Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total		119,257		119,257
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	2,874	2,813	2,874	2,813
Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	103	613	103	613
Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	119	53	119	53
Convertible Debt
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total		42,771		42,771

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Provision for income taxes			$ 0
Cash paid for income taxes	$ 0	$ 0	$ 0	$ 0

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Commitments and Contingencies - Additional Information (Details) - USD ($)				1 Months Ended		3 Months Ended		6 Months Ended
	May 13, 2021	May 01, 2021	Dec. 02, 2020	Sep. 30, 2020	Aug. 31, 2019	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Oct. 31, 2016
Loss Contingencies [Line Items]
Rent expense						$ 300,000	$ 500,000	$ 600,000	$ 1,100,000
Research and development						3,323,000	2,107,000	$ 6,644,000	5,007,000
Revenue Share Agreement \| Oncimmune Limited
Loss Contingencies [Line Items]
Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests								8.00%
Minimum annual volume percentage thereafter								5.00%
Period of escalations of sales								through the first four years of sales
Revenue share expenses						100,000	100,000	$ 300,000	200,000
Bio-Rad License
Loss Contingencies [Line Items]
Percentage of royalty payments on net revenue					2.50%
Percentage of royalty payments not required on net revenue		2.50%
License expiry date					2024-08
CellCarta License
Loss Contingencies [Line Items]
Percentage of royalty payments on net revenue	0.675%
Percentage of fee payments on net sales	1.00%
Term of royalty payments from first commercial sale	15 years
Year of ending royalty payments from first commercial sale	2034
Royalty expense						100,000		100,000
AVEO Oncology
Loss Contingencies [Line Items]
Remaining estimated obligation								300,000
Research and development						$ 0	$ 100,000	$ 0	$ 700,000
AVEO Oncology \| NSCLC POC Trial
Loss Contingencies [Line Items]
Responsible percentage of development and regulatory costs										50.00%
Ficlatuzumab \| AVEO Oncology
Loss Contingencies [Line Items]
Percentage of development and regulatory costs exercised using opt-out right				50.00%
Percentage of royalty payments on net sales			10.00%
Percentage of license income generated from licensing			25.00%
BDX004 \| Ficlatuzumab \| AVEO Oncology \| POC Clinical Trials
Loss Contingencies [Line Items]
Responsible percentage of development and regulatory costs										50.00%

Commitments and Contingencies - Summary of Future Minimum Lease Payments for Operating Lease Obligations (Details) $ in Thousands	Jun. 30, 2021 USD ($)
Leases [Abstract]
Remainder of 2021	$ 352
2022	724
2023	112
Total	$ 1,188